ArticleCureus2026
Managing Antithrombotic Treatment in Intracerebral Hemorrhage and Ischemic Stroke Due to Cerebral Amyloid Angiopathy With Supporting Pathology.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral amyloid angiopathy (CAA) is a small vessel disease marked by β-amyloid deposition within cortical and leptomeningeal vessels. It is associated with a range of hemorrhagic manifestations, including lobar intracerebral hemorrhage (ICH), cortical superficial siderosis, and convexity subarachnoid hemorrhage (cSAH). In addition to hemorrhagic complications, cerebral ischemic events may occur due to impaired vascular reactivity and reduced cerebral perfusion. The coexistence of ischemic and hemorrhagic strokes in patients with biopsy-confirmed CAA poses significant diagnostic and therapeutic challenges, particularly in relation to antithrombotic use. A 74-year-old woman with type 2 diabetes mellitus and dyslipidemia initially presented with transient focal neurological deficits and subsequently developed left parietal cSAH along with multiple acute infarcts involving the left parietal, temporal, and centrum semiovale regions, for which aspirin and rivaroxaban were initiated. Over the following years, she developed progressive cognitive decline. Three years after her ischemic event, she experienced a lobar ICH in the right frontotemporoparietal region and later suffered another ischemic stroke, prompting treatment with cilostazol. This case illustrates the coexistence of ischemic and hemorrhagic pathology in CAA. Recurrent lobar ICH is a characteristic feature of CAA; however, ischemic events may also occur during its course and can adversely affect prognosis. The lack of clear guidance regarding antithrombotic therapy further complicates management. In this context, cilostazol was selected due to its favorable safety profile in patients at high risk of hemorrhage. This approach underscores the importance of individualized treatment strategies in CAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.